Previous 10 | Next 10 |
UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA ® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150...
Amarin Corporation plc 2022 Jefferies Global Healthcare Conference Call June 8, 2022 1:00 P.M. ET Company Participants Karim Mikhail - President and Chief Executive Officer Conference Call Participants Michael Yee - Jefferies Presentation Michael Yee Thank you. Well, good afternoon, everyone,...
Penny stocks are great tools to make money in the stock market. While they don’t come without risk, there are plenty of ways to ensure you find the top names to watch. One of the first steps is looking for specific catalysts. These could be anything from unusual trading activity to m...
Amarin Corp. (NASDAQ:AMRN) will undertake an organizational restructuring plan in an effort to save $100M over the next year. Shares are up 8% in premarket trading. This will result in a 90% reduction of its U.S. commercial team based on where it was before the pandemic and introduc...
-- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion -- -- Reduces U.S. Commercial Organization by Ninety Percent of Pre-Pandemic / Pre-Generic Competition Levels --...
Amarin Corporation (NASDAQ:AMRN) has appointed Tom Reilly as Chief Financial Officer, effective June 20, 2022, following the resignation of Michael W. Kalb. Michael is stepping down to pursue other interests. Most recently, Tom Reilly served as Chief Financial Officer for Cara Thera...
-- Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin -- -- Michael W. Kalb to Depart Amarin to Pursue Other Interests -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) t...
An important shareholder is agitating for change at Amarin (NASDAQ: AMRN) . Will this lead to meaningful improvements, or even put the company in play? Some investors are clearly hoping for one of these outcomes, following regulatory filings submitted by both the company and one...
The ADRs of Ireland-based biotech Amarin Corporation (NASDAQ:AMRN) have risen ~6% in the morning hours Friday after activist investor Sarissa Capital Management said it planned to seek representation in the company’s board of directors. It has already conducted discussions wi...
Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
2024-07-31 14:15:16 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q2 2024 Earnings Call Jul 31, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
Dayforce Inc. (DAY) is expected to report $0.18 for Q2 2024 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.44 for Q2 2024 Aurora Innovation Inc. (AUR) is expected to report for Q2 2024 Autohome Inc. American Depositary Shares each repr...
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...